[HTML][HTML] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F Xie, F Wang, L Fu - Journal of Hematology & Oncology, 2022 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F Xie, F Wang, L Fu - Journal of Hematology & Oncology, 2022 - search.proquest.com
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F Xie, F Wang, L Fu - Journal of hematology & …, 2022 - pubmed.ncbi.nlm.nih.gov
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
[HTML][HTML] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F Xie, F Wang, L Fu - … of Hematology & …, 2022 - jhoonline.biomedcentral.com
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.
K Fu, F Xie, F Wang, L Fu - Journal of Hematology & …, 2022 - search.ebscohost.com
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.
K Fu, F Xie, F Wang, L Fu - Journal of Hematology & Oncology, 2022 - europepmc.org
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
[HTML][HTML] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F Xie, F Wang, L Fu - Journal of Hematology & Oncology, 2022 - ncbi.nlm.nih.gov
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
[引用][C] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F Xie, F Wang, L Fu - 2022 - europepmc.org
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced nonsmall cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced nonsmall cell lung cancer (NSCLC) patients harboring EGFR …
[PDF][PDF] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F Xie, F Wang, L Fu - 2022 - jhoonline.biomedcentral.com
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced nonsmall cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced nonsmall cell lung cancer (NSCLC) patients harboring EGFR …